BioTech Mag Search: Research
How accumulating useful genes helps older yeast fare better in tougher times
7 days ago - By Phys
Genome amplification, whereby organisms bump up the number of copies of beneficial genes in response to environmental stresses, is implicated in diseases such as cancer and also in ageing. Researchers in the Babraham Institute's Epigenetics research programme have used yeast to learn more about how satellite DNA circles are formed to carry amplified genes, how the gene duplication is specific to the environmental pressure and the effects of age. Their research is published today in the journal PLOS Biology.
Read more ...Researchers use genomics to discover potential new treatment for parasite disease
7 days ago - By Phys
Using innovative RNA sequencing techniques, researchers at the University of Maryland School of Medicine Institute for Genome Sciences identified a promising novel treatment for lymphatic filariasis, a disabling parasitic disease that is difficult to treat. The potential new therapy is an experimental cancer drug called JQ1 and targets proteins found prominently in the worm's genome; it appears to effectively kill the adult worms in a laboratory setting, according to the study which was published today in the journal mSystems.
Read more ...
The headlines of BioTech Mag
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs
Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at...
Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego's Synthorx
Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions...
Flagship's Cellarity Aims to Advance Cell Behavior-Based Therapeutics
The latest startup to emerge from Flagship Pioneering aims to change drug discovery by starting the process with a clear understanding of cell behavior. Cellarity-like many...
KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test
A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat...
Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules
Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the...
Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer
The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other...
Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals
Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3...
Artificial Pancreas Keeps Patients Healthier: A Perspective
The late Mayo endocrinologists Russell Wilder, M.D., and Randall Sprague, M.D., would be smiling today at the news for patients with diabetes. Much of their lives and careers...
Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule
Merck is acquiring cancer drug developer ArQule for $2.7 billion , a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug...
AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets
After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and...